| abstract |
Use of a group of aryl ureas that are inhibitors of the enzyme raf kinase for treating raf mediated diseases is disclosed, wherein these inhibitors are useful in pharmaceutical compositions for human or veterinary use where inhibition of the raf kinase pathway is indicated, e.g., in the treatment of tumors and/or cancerous cell growth mediated by raf kinase. In particular, these compounds are useful in the treatment of human or animal, e.g., murine cancer. |